Clinical Trials Browser

Neoplasm, Residual × tetrathiomolybdate × 90 days × Clear all

NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms